Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946568 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.
A Phase 1 study, sponsored by Durata Therapeutics Inc., an affiliate of Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01946568 is a Phase 1 study that has completed, run by Durata Therapeutics Inc., an affiliate of Allergan. The registered enrollment target is 36 participants.
The verdict
NCT01946568, a Phase 1 study, has completed, sponsored by Durata Therapeutics Inc., an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
Interventions
- DRUG Dalbavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946568
The ClinicalTrials.gov registry entry for NCT01946568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durata Therapeutics Inc., an affiliate of Allergan, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalbavancin is the first listed.
NCT01946568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01946568 about?
NCT01946568 is a clinical study titled "A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.". A phase one study to characterize the pharmacokinetics of dalbavancin in pediatric patients aged 3 months to 11 years (inclusive) following the intravenous administration of a single dose of dalbavancin.
What is the current status of trial NCT01946568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-06. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01946568?
The interventions under investigation include: Dalbavancin (DRUG).
Who is sponsoring clinical trial NCT01946568?
This trial is sponsored by Durata Therapeutics Inc., an affiliate of Allergan, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.